Home
Login
Register
Live
Users
Tag cloud
Published News
Upcoming News
Submit a new story
World Pharma News Home
»
Blogs
»
Drug Injury Watch: Mylan's Corporate Motto, Actavis On The Meaning Of GMP, And Who Is Ulitimately Responsible For The Digitek Fiasco
->
Get all Published News delivered to your inbox!
(a free service delivered by FeedBurner)
2
Vote
Drug Injury Watch: Mylan's Corporate Motto, Actavis On The Meaning Of GMP, And Who Is Ulitimately Responsible For The Digitek Fiasco
Posted by
tjlpa
65 days ago
(
http://www.drug-injury.com
)
View profile
Category
:
Blogs
|
Tags
:
digitek
drug-safety
drug-injury
fda
FDA Statement Suggests Actavis Will Be Held Accountable For The Defective Digitek Pills, And Mylan Maintains That This Is Not My(lan) Problem
Discuss
Add this link to...
Bury
Add to:
|
Bookmarks
Comments
Who Voted
Related Links
Comments
Log in to comment
or register
here
.
Who voted for this story
tjlpa
worldpharmanews
Related Links
Drug Injury Watch: Digitek Digoxin Recall: Tablets May Be Double The Normal Dose
Drug Injury Watch: FDA Says It Doesn't Know How Long Defective Digitek / Digoxin Pills Were Sold
Drug Injury Watch: Extent Of Digitek Recall Remains A Mystery Ten Days Later; Patients Are Left In The Dark
Drug Injury Watch: Recall Notice For Digitek Marketed Under Bertek Label Goes Back To March 2006
Drug Injury Watch: Actavis Tells Us More, But Not Much More, About Extent Of Digitek Recall
Drug Injury Watch: Another "Double-Dose" Pill Problem Demonstrates How And Why The Digitek Recall Is So Unusual
What is World Pharma News?
World Pharma News .net is the first worldwide Web 2.0 pharmaceutical news service developed on the top of the World Pharma News .com Project.
Login
|
Register
Top Today
1
ADAGIO trial results show Azil...
1
Study overturns century-old ru...
Published News
1
Study overturns century-old ru...
1
ADAGIO trial results show Azil...
2
Drug Injury Watch: August 2008...
2
Drug Injury Watch: FDA Warns S...
1
Brings complementary capabilit...
Categories
Blogs
Clinical Trials
Conferences & Events
Corporate
Financial
Product
Publications
Research & Development
Top Tags
bayer
drug-injury
drug-safety
fda
glaxosmithkline
novartis
pfizer
pharma
pharmalot
preemption
read more
Comments